Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-09-29
2000-12-05
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514956, A61K 3135, A61K 3156, C07D30910, C07D40706
Patent
active
061567922
ABSTRACT:
Mupirocin or a salt or ester thereof may be used to treat recurrent sinusitis and recurrent otitis, in particular with novel spray or cream formulations adapted for administration to the nasopharynx
REFERENCES:
patent: 4790989 (1988-12-01), Hunter et al.
patent: 4879287 (1989-11-01), Orr et al.
patent: 4916155 (1990-04-01), Baker et al.
patent: 5594026 (1997-01-01), Greenway et al.
patent: 5714165 (1998-02-01), Repka et al.
patent: 5985291 (1999-11-01), De Wet
patent: 6001870 (1999-12-01), Henkel
patent: 6025389 (2000-02-01), Zimmerman
Bertino, "Intranasal Mupirocin for Outbreaks of Methicillin-Resistant Staphylococcus aureus", Am. J. Health Syst. Pharm. (Abstract only) 54(19): 2185-2191 (1997).
Nakagawa, et al. "Antimicrobial Pharmacology of Mupirocin Nasal Ointments", Kagaku Ryoho no Ryoiki, (Abstract only) 12(9): 1659-1667 (1996).
Anon, "Nasal Mupirocin Prevents Staphylococcus aureus Exit Site Infection During Peritoneal Dialysis", J. Am. Soc. Nephrol., (Abstract only) 7(11): 2403-2408 (1996).
Nakagawa, et al. "Stability and Physicochemical Properties of Bactroban Nasal Ointment", Kagaku Ryoho no Ryoiki, (Abstract only) 12(7): 1293-1296 (1996).
Finlay, et al. "Interpretive Criteria for Testing Susceptibility of Staphylococci to Mupirocin", Antimicrob. Agents Chemother. (Abstract only) 41(5): 1137-1139 (1997).
Nakamichi, et al., "Dermal Irritancy Study of Mupirocin Ointment: A Study on the Irritant Potential of Mupirocin Ointment to the Skin and Nasal Mucosa in Healthy Adult Volunteers", Yakuri to Chiryo, (Abstract only) 24(1): 85-92 (1996).
Raz, et al., "A 1-Year Trial of Nasal Mupirocin in the Prevention of Recurrent Staphylococcal Nasal Colonization and Skin Infection", Arch. Intern. Med. (Abstract only) 156(10): 1109-1112 (1996).
Bloom, et al., "Clinical and Economic Effects of Mupirocin Calcium on Preventing Staphylococcus aureus Infection in Hemodialysis Patients: A Decision Analysis", Am. J. Kidney Dis., (Abstract only) 27(5): 687-694 (1996).
Nsouli, et al., "Nasal Topical Antimicrobial Agent, Mupirocin-(Bactroban), in the Prophylaxis of Repeated Paranasal Sinusitis (RPS): A Double Blind Placebo Control Study", Annals. of Allergy, Asthma and Immunology, vol. 76(1): pp. 117, (1996).
"Mupirocin", Merck Index, 11th edn., pp. 993, (1989).
Boyce, et al., "Spread of Methicillin-Resistant Staphylococcus aureua in a Hospital After Exposure to a Health Care Worker with Chronic Sinusitis", Clinical Infectious Diseases, 17, pp. 496-504 (1993).
Hatton Anthony Guy
Hilton Jane Elizabeth
Scott Hugh
Hecht Elizabeth J.
King William T.
Kinzig Charles M.
Rose Shep K.
SmithKline Beecham Corporation
LandOfFree
Calcium mupirocin non-aqueous nasal spray for otitis media or fo does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Calcium mupirocin non-aqueous nasal spray for otitis media or fo, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Calcium mupirocin non-aqueous nasal spray for otitis media or fo will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-962202